TScan Therapeutics Reports Third Quarter 2022 Financial Results and Provides Business UpdateGlobeNewsWire • 11/09/22
TScan Therapeutics Announces Upcoming Poster Presentation at the 64th American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 11/03/22
TScan Therapeutics Announces Upcoming Poster Presentations at the 37th Society for Immunotherapy of Cancer Annual MeetingGlobeNewsWire • 10/05/22
TScan Therapeutics Secures Convertible Debt Facility for up to $60 Million with K2 HealthVenturesGlobeNewsWire • 09/12/22
TScan Therapeutics to Participate in the Morgan Stanley 20th Annual Global Healthcare ConferenceGlobeNewsWire • 09/07/22
TScan Therapeutics Reports Second Quarter 2022 Financial Results and Highlights Recent ProgressGlobeNewsWire • 08/10/22
TScan Therapeutics to Participate in the 13th Annual Wedbush PacGrow Healthcare ConferenceGlobeNewsWire • 08/03/22
TScan Therapeutics Announces Publication in Cell Highlighting the Discovery of Tumor Antigens and TCRs for the Treatment of Solid Tumors Using Foundational Screening TechnologyGlobeNewsWire • 07/11/22
TScan Therapeutics to Participate in the LifeSci 2nd Annual Genetic Medicines SymposiumGlobeNewsWire • 06/22/22
TScan Therapeutics to Participate in the 2022 Jefferies Healthcare ConferenceGlobeNewsWire • 06/02/22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-101 for the Treatment of Hematologic MalignanciesGlobeNewsWire • 05/31/22
TScan Therapeutics Presents Preclinical Data at the American Society of Gene and Cell Therapy 25th Annual MeetingGlobeNewsWire • 05/19/22
TScan Therapeutics to Participate in the H.C. Wainwright Global Investment ConferenceGlobeNewsWire • 05/17/22
TScan Therapeutics to Host Virtual KOL Event to Discuss its Solid Tumor Program Strategy and Highlights from the ASGCT 25th Annual MeetingGlobeNewsWire • 05/12/22
TScan Therapeutics Reports First Quarter 2022 Financial Results and Upcoming Anticipated MilestonesGlobeNewsWire • 05/09/22
TScan Therapeutics Announces Upcoming Presentations at the 25th American Society of Gene and Cell Therapy Annual MeetingGlobeNewsWire • 05/02/22
TScan Therapeutics Appoints Leiden Dworak, CPA, MBA, as Vice President, FinanceGlobeNewsWire • 04/11/22
TScan Therapeutics Reports Full Year 2021 Financial Results and Highlights Key 2022 PrioritiesGlobeNewsWire • 03/09/22
TScan Therapeutics Announces Presentation at the 11th Annual SVB Leerink Global Healthcare ConferenceGlobeNewsWire • 02/10/22
FDA Gives Nod To TScan Therapeutics' Early-Stage Trial Of TSC-100 In Hematologic MalignanciesBenzinga • 01/24/22
TScan Therapeutics Announces FDA Clearance of Investigational New Drug Application for TSC-100 for the Treatment of Hematologic MalignanciesGlobeNewsWire • 01/24/22
TScan Therapeutics Announces Poster Presentations at the 63rd American Society of Hematology Annual Meeting and ExpositionGlobeNewsWire • 12/13/21